Officer and Director Stock Option Grant

Maria Fardis, a director at CRISPR Therapeutics AG, was granted 13,000 stock options on June 5, 2026. These options, with a right to buy underlyling common shares, have an exercise price of $51.84 and expire on June 5, 2036. The options will vest in 12 equal monthly installments starting June 30, 2026, contingent upon continued service to the company. The final installment vests one year after the grant date or at the 2027 Annual Meeting, whichever comes first. This transaction was reported on Form 4, filed on June 9, 2026.